We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gene Test Validated for Breast Cancer Therapy

By LabMedica International staff writers
Posted on 12 Oct 2015
Print article
Image: The Oncotype DX specimen and collection kit for Breast Cancer Recurrence Score Assay (Photo courtesy of Genomic Health).
Image: The Oncotype DX specimen and collection kit for Breast Cancer Recurrence Score Assay (Photo courtesy of Genomic Health).
A genetic test has been clinically validated in predicting which patients with early-stage breast cancer are unlikely to benefit from chemotherapy.

Many women with hormone receptor-positive breast cancers also undergo chemotherapy in order to destroy any cancer cells that many have spread beyond the breast and reduce the risk of recurrence. While some of these women may not need chemotherapy, there is currently no effective way of determining which women could safely avoid the treatment.

A large team of scientists led by those at the Montefiore Medical Center (Bronx, NY, USA) used a 21-gene expression assay on 10,273 women ages 18 to 75 who had early-stage, hormone receptor-positive breast cancer, whereby the cancer is driven by estrogen or progesterone and that did not overexpress human epidermal growth factor receptor (HER2). Prospective validation was performed with the use of archival tumor specimens from completed studies that used a prospective–retrospective design.

All the patients had an Oncotype DX Recurrence Score (Genomic Health, Redwood City, CA, USA), a reverse-transcriptase–polymerase-chain-reaction 21-gene assay performed on ribonucleic acid (RNA) extracted from formalin-fixed paraffin-embedded tissue, performed in a central laboratory. Patients with a score of 0 to 10 were assigned to receive endocrine therapy alone, and those with a score of 26 or higher were assigned to receive chemotherapy plus endocrine therapy.

A total of 1,626 of whom were eligible, which was 15.9% of the total eligible population had a recurrence score of 0 to 10 (indicating low risk), 6,897 of whom were eligible which was 67.3% of the total eligible population had a score of 11 to 25 (indicating midrange risk), and 1,730 of whom were eligible being16.9% of the total eligible population, had a score of 26 or higher (indicating high risk). The median follow-up in the low-risk cohort was 69 months. The team found that around 99% of low-risk women treated with hormone therapy alone did not experience breast cancer recurrence within five years. Furthermore, the rate of invasive disease-free survival at five years was almost 94%, while the risk of cancer returning at a distant site was less than 1%.

The authors concluded that their prospective study involving uniformly treated patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer supports the clinical validity of the 21-gene assay in identifying patients who may be safely spared adjuvant chemotherapy. Joseph A. Sparano, MD, the lead authors of the study, said, “The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk-stratify patients with early-stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice.” The study was published on September 28, 2015, in the New England Journal of Medicine.

Related Links:

Montefiore Medical Center
Genomic Health 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.